Comparison of monotherapy with irbesartan and telmisartan for treatment of essential hypertensive patients - interventional, parallel group study using home Blood Pressure monitoring -

Comparison of monotherapy with irbesartan and telmisartan for treatment of essential hypertensive patients - interventional, parallel group study using home Blood Pressure monitoring - - Comparison of monotherapy with irbesartan and telmisartan for treatment of essential hypertensive patients

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004491

Enrollment

Registered

2010-11-15

Start date

2010-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Essential hypertension

Interventions

Treatment of irbesartan 50-200mg/day Treatment of telmisartan 20-80mg/day

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Essential hypertensive outpatients who are without antihypertensive drug at least 4 weeks prior to randomization or without a historiy of anti-hypertensive drug 2) Office SBP >=140mmHg or DBP >=90 3) Age >=30 years 4) Subjects who gave written informed consent

Exclusion criteria

Exclusion criteria: 1) Allergy against irbesartan/telmisartan 2) History of stroke, acute coronary syndrome or any cardiovascular diseases needed for inpatient-treatments 3) Impaired renal function (Cre>=2.0mg/dL) 4) Biliary obstructive disorders or level of alanine aminotransferase >= 100IU 5) Symptomatic (NYHA II, III or IV) congestive heart failure 6) Poor-controlled hypertension (SBP>=180, or DBP>=110 mmHg in office BP) 7) Severe arrythmia 8) Diabetes treated with thiazolidine 9) Malignancies or other diseases with poor prognosis 10) Pregnant 11) Subjects whose doctor in charge do not agree to join the trial

Design outcomes

Primary

Measure	Time frame
To compare the changes from baseline in home Systolic Blood Pressure between 12 week treatments of irbesartan and telmisartan	—

Secondary

Measure	Time frame
1.To compare the percents of achieving blood pressure targets in home Blood Pressure monitoring between 12 week treatments of irbesartan and telmisartan 2.To compare the changes from baseline in office blood pressure, home diastolic Blood Pressure, heart rates between 12 week treatments of irbesartan and telmisartan 3.To compare the changes from baseline in LDL-C, HDL-C, TG, FFA, FBS, HbA1C, UACR between 12 week treatments of irbesartan and telmisartan 4.To compare the changes from baseline in blood and urine examinations between 12 week treatments of irbesartan and telmisartan	—

Measure

Time frame

1.To compare the percents of achieving blood pressure targets in home Blood Pressure monitoring between 12 week treatments of irbesartan and telmisartan 2.To compare the changes from baseline in office blood pressure, home diastolic Blood Pressure, heart rates between 12 week treatments of irbesartan and telmisartan 3.To compare the changes from baseline in LDL-C, HDL-C, TG, FFA, FBS, HbA1C, UACR between 12 week treatments of irbesartan and telmisartan 4.To compare the changes from baseline in blood and urine examinations between 12 week treatments of irbesartan and telmisartan

—

Countries

Japan

Contacts

Public ContactHitoshi Ishihara

Nishi-Mikawa SG-ARB association Ishihara medical clinic

0564-22-2167

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026